Core Insights - Celsius Holdings Inc. reported quarterly earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, compared to break-even earnings per share a year ago, representing an earnings surprise of +50.00% [1] - The company posted revenues of $725.11 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.61%, and showing significant growth from year-ago revenues of $265.75 million [2] - Celsius shares have increased approximately 127.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $684.84 million, and for the current fiscal year, it is $1.12 on revenues of $2.47 billion [7] - The estimate revisions trend for Celsius was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Zacks Industry Rank for Food - Miscellaneous is currently in the bottom 31% of over 250 Zacks industries, suggesting that the industry outlook may impact stock performance [8] - Another company in the same industry, BellRing Brands, is expected to report quarterly earnings of $0.54 per share, reflecting a year-over-year change of +5.9%, with revenues anticipated to be $631.33 million, up 13.6% from the previous year [9][10]

分组1 - Lamar Advertising reported quarterly funds from operations (FFO) of $2.2 per share, exceeding the Zacks Consensus Estimate of $2.14 per share, and showing an increase from $2.15 per share a year ago, resulting in an FFO surprise of +2.80% [1] - The company achieved revenues of $585.54 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.29% and increasing from $564.14 million year-over-year [2] - Over the last four quarters, Lamar has surpassed consensus FFO estimates three times, but has only topped consensus revenue estimates once [2] 分组2 - The stock has underperformed, losing about 2.7% since the beginning of the year, while the S&P 500 has gained 15.6% [3] - The future performance of Lamar's stock will depend on management's commentary during the earnings call and the outlook for FFO [3][4] - The current consensus FFO estimate for the upcoming quarter is $2.22 on revenues of $596.24 million, and for the current fiscal year, it is $8.14 on revenues of $2.26 billion [7] 分组3 - The Zacks Industry Rank indicates that the REIT and Equity Trust - Other industry is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Lamar was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Core Insights - LifeStance Health Group (LFST) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.01, and showing improvement from a loss of $0.02 per share a year ago, resulting in an earnings surprise of +100.00% [1] - The company achieved revenues of $363.81 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 2.30% and up from $312.72 million in the same quarter last year [2] - LifeStance Health has outperformed consensus EPS estimates in all four quarters over the past year and has topped revenue estimates three times during the same period [2] Financial Performance - The company's shares have declined approximately 34.7% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The current consensus EPS estimate for the upcoming quarter is breakeven on revenues of $383.44 million, while for the current fiscal year, the estimate is -$0.02 on revenues of $1.42 billion [7] Industry Outlook - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Privia Health reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share, but showing an increase from $0.03 per share a year ago, resulting in an earnings surprise of -16.67% [1] - The company posted revenues of $580.42 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 16.64%, and up from $437.92 million year-over-year [2] Market Performance - Privia Health shares have increased approximately 28% since the beginning of the year, outperforming the S&P 500's gain of 15.6% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $516.3 million, and for the current fiscal year, it is $0.18 on revenues of $2.02 billion [7] - The Zacks Rank for Privia Health is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Privia Health belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Yeti (YETI) reported quarterly earnings of $0.61 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, but down from $0.71 per share a year ago, representing an earnings surprise of +7.02% [1] - The company achieved revenues of $487.77 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.85% and showing an increase from $478.44 million year-over-year [2] - Yeti has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.87 on revenues of $574.29 million, and for the current fiscal year, it is $2.41 on revenues of $1.85 billion [7] - The estimate revisions trend for Yeti was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Leisure and Recreation Products industry, to which Yeti belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Esperion Therapeutics reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking a surprise of -77.78% [1] - The company achieved revenues of $87.31 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.75% and showing significant growth from $51.63 million a year ago [2] - Esperion's stock has increased by approximately 33.6% since the beginning of the year, outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The earnings outlook for Esperion is mixed, with the current consensus EPS estimate for the upcoming quarter at $0.10 on revenues of $137.02 million, and for the current fiscal year at -$0.05 on revenues of $365.54 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Esperion belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of Esperion's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]

Group 1: Earnings Performance - A.P. Moller-Maersk reported quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.51 per share, and down from $0.99 per share a year ago, representing an earnings surprise of -39.22% [1] - The company posted revenues of $14.21 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 3.05%, and down from $15.76 billion year-over-year [2] Group 2: Market Performance - A.P. Moller-Maersk shares have increased by approximately 26.4% since the beginning of the year, outperforming the S&P 500's gain of 15.6% [3] Group 3: Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $12.74 billion, and for the current fiscal year, it is $1.08 on revenues of $53.85 billion [7] - The Zacks Industry Rank indicates that the Transportation - Shipping sector is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]

Core Insights - Flora Growth Corp. reported a quarterly loss of $4.93 per share, significantly worse than the Zacks Consensus Estimate of a loss of $2.13, marking an earnings surprise of -131.46% [1] - The company's revenues for the quarter ended September 2025 were $9.75 million, missing the Zacks Consensus Estimate by 22.14%, and down from $12.47 million a year ago [2] - Flora Growth shares have declined approximately 76.7% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Financial Performance - The company has not surpassed consensus EPS estimates over the last four quarters, indicating ongoing challenges in meeting market expectations [2] - The current consensus EPS estimate for the upcoming quarter is -$1.97 on revenues of $11.56 million, and for the current fiscal year, it is -$23.01 on revenues of $50.66 million [7] Market Outlook - The Zacks Rank for Flora Growth is currently 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] - The Medical - Products industry, to which Flora Growth belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may negatively impact stock performance [8]

Core Insights - SEMrush Holdings, Inc. reported quarterly earnings of $0.08 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.06 per share a year ago [1] - The company achieved revenues of $112.08 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.49% and up from $97.41 million year-over-year [2] - SEMrush shares have declined approximately 40.4% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Earnings Performance - The earnings surprise for the previous quarter was -37.5%, as the company reported earnings of $0.05 per share against an expectation of $0.08 [1] - Over the last four quarters, SEMrush has not surpassed consensus EPS estimates [1] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $118.46 million, and for the current fiscal year, it is $0.33 on revenues of $443.3 million [7] - The estimate revisions trend for SEMrush was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Internet - Software industry, to which SEMrush belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

分组1 - RCM Technologies, Inc. reported quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.45 per share, and showing a decrease from $0.44 per share a year ago, resulting in an earnings surprise of -6.67% [1] - The company posted revenues of $70.29 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.97%, and an increase from $60.37 million year-over-year [2] - Over the last four quarters, RCM Technologies has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] 分组2 - The stock has added about 4.1% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.1% [3] - The current consensus EPS estimate for the coming quarter is $0.61 on $83 million in revenues, and for the current fiscal year, it is $2.38 on $313.91 million in revenues [7] - The Zacks Industry Rank indicates that the Staffing Firms industry is currently in the bottom 15% of over 250 Zacks industries, which may impact stock performance [8]